Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Antiviral treatment of G1b Treatment-Naïve HCV-Infected Patients, with non- severe fibrosis,
with or without insulin resistance (IR) and/or diabetes mellitus (DM) with EBR/GZR Fixed-Dose
Combination for 8 Weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo